introduct
sinc
acut
respiratori
tract
infect
inflict
high
burden
diseas
children
worldwid
multiplex
revers
transcript
polymeras
chain
reaction
combin
microwel
hybrid
assay
mrtpcrelisa
detect
differ
respiratori
pathogen
develop
valid
method
total
respiratori
specimen
retrospect
test
parallel
advanc
mrtpcrelisa
well
cultur
individu
rtpcr
assay
use
clinic
routin
mean
median
sensit
mrtpcrelisa
retrospect
test
rang
mean
median
specif
rang
respect
mean
posit
predict
valu
rang
mean
neg
predict
valu
rang
feasibl
clinic
valu
method
prospect
shown
incom
clinic
specimen
patient
year
age
acut
respiratori
tract
infect
admit
pediatr
hospit
privat
practic
octob
june
three
region
germani
kiel
mainz
freiburg
freiburg
june
least
one
microorgan
detect
clinic
specimen
rv
rsv
av
ev
season
iva
pandem
iva
mpv
cv
mpn
ivb
bp
cpn
bpp
reoviru
lpn
present
specimen
pediatr
popul
one
organ
could
detect
specimen
conclus
mrtpcrelisa
evalu
improv
spectrum
diagnos
respiratori
infect
feasibl
instrument
individu
diagnost
epidemiolog
studi
keyword
mrtpcrelisa
respiratori
tract
infect
valid
sensit
diagnosi
enteroviru
ev
influenza
viru
type
iva
influenza
viru
type
b
ivb
respiratori
syncyti
viru
rsv
parainfluenza
viru
type
parainfluenza
viru
type
parainfluenza
viru
type
parainfluenza
viru
type
adenoviru
av
rhinoviru
rv
human
metapneumoviru
mpv
coronaviru
cv
reoviru
reov
mycoplasma
pneumonia
mpn
chlamydophila
pneumonia
cpn
bordetella
pertussi
bp
bordetella
parapertussi
bpp
legionella
pneumophila
lpn
acut
respiratori
tract
infect
inflict
high
burden
diseas
children
worldwid
import
caus
like
streptococcu
pneumonia
haemophilu
influenza
moraxella
catarrhali
commens
upper
respiratori
tract
viral
bacteri
agent
consid
regular
pathogen
detect
clinic
specimen
consid
proof
infect
includ
enteroviru
ev
influenza
viru
type
iva
type
b
ivb
respiratori
syncyti
viru
rsv
parainfluenza
viru
type
type
type
type
adenoviru
av
rhinoviru
rv
human
metapneumoviru
mpv
coronaviru
cv
reoviru
rv
mycoplasma
pneumonia
mpn
chlamydophila
pneumonia
cpn
bordetella
pertussi
bp
bordetella
parapertussi
bpp
legionella
pneumophila
lpn
molecular
amplif
techniqu
advantag
compar
cultur
techniqu
result
avail
earlier
lower
cost
higher
sensit
moreov
diagnost
laboratori
handl
viabl
pathogen
requir
group
develop
use
multiplex
polymeras
chain
reaction
pcr
test
acut
respiratori
infect
ari
pathogen
sinc
allow
comprehens
laboratorybas
surveil
meantim
addit
method
describ
previous
report
multiplex
revers
transcript
polymeras
chain
reaction
combin
microwel
hybrid
assay
mrtpcrelisa
allow
simultan
detect
nine
import
respiratori
pathogen
rna
virus
ev
iva
ivb
rsv
dna
viru
av
well
bacteria
cpn
mpn
feasibl
mrtpcrelisa
clinic
specimen
test
valid
diagnosi
respiratori
tract
infect
clinic
specimen
cultur
supernat
comparison
refer
gold
standard
descript
epidemiolog
studi
base
result
obtain
method
report
present
studi
describ
advanc
mrtpcrelisa
detect
rna
virus
ev
rv
iva
ivb
rsv
mpv
reov
dna
viru
av
well
bacteria
cpn
mpn
bp
bpp
lpn
valid
mrtpcr
four
differ
approach
use
supernat
cell
cultur
neg
control
blind
use
valid
previous
describ
mrtpcr
receiv
differ
laboratori
ii
analyt
sensit
multiplex
approach
comparison
correspond
singl
primer
test
determin
cultur
supernat
organ
iii
clinic
specimen
frozen
stock
collect
institut
virolog
rotterdam
netherland
test
mrtpcr
techniqu
versu
cultur
sensit
specif
call
retrospect
test
clinic
specimen
kiel
store
viru
medium
thu
use
viru
cultur
known
result
reduc
sensit
avoid
bia
retrospect
test
clinic
specimen
depart
virolog
rotterdam
store
viru
medium
calf
serum
use
specimen
use
part
evalu
n
nasopharyng
aspir
swab
bronchoalveolar
lavag
bal
gold
standard
defin
result
cultur
secondari
rtpcr
extern
laboratori
sequenc
inform
deriv
organ
detect
one
method
within
specimen
especi
differenti
within
picornaviru
group
ev
rv
total
specimen
sputum
one
bal
patient
histor
character
legionella
pneumophila
case
three
neg
control
sputum
obtain
dr
ijzerman
haarlem
netherland
legionella
case
defin
one
diagnost
test
urinari
antigen
cultur
pcr
histor
perform
haarlem
posit
specimen
retest
kiel
mrtpcrelisa
sinc
retest
specimen
cultur
individu
pcr
haarlem
may
becom
neg
due
long
storag
specimen
histor
determin
posit
case
use
standard
sensit
calcul
total
clinic
specimen
ami
swab
transport
system
nasopharyng
aspir
test
cultur
method
bordetellaselect
media
oxoid
wesel
germani
differenti
agglutin
test
use
sera
b
pertussi
b
parapertussi
genzym
virotech
gmbh
germani
individu
bordetella
pcr
presenc
b
pertussi
b
parapertussi
parallel
mrtpcrelisa
perform
furthermor
specimen
patient
typic
clinic
symptom
test
individu
bordetella
pcr
protocol
comparison
mrtpcrelisa
retrospect
studi
iii
clinic
specimen
thaw
divid
one
aliquot
sent
dri
ice
laboratori
kiel
arriv
specimen
immedi
store
without
thaw
use
retest
cell
cultur
rotterdam
mrtpcrelisa
kiel
sampl
blind
real
content
sampl
disclos
result
test
reveal
cooper
laboratori
mpn
cpn
clinic
specimen
avail
evalu
extern
laboratori
therefor
mpn
seven
cpn
blind
cultur
supernat
test
furthermor
cultur
supernat
adenoviru
type
type
type
type
test
multiplex
approach
test
sensitivityspecif
method
pathogen
comparison
test
could
done
reoviru
clinic
blind
cultur
supernat
avail
cultur
supernat
reoviru
type
could
test
posit
control
influenza
plasmid
kindli
provid
dr
schweiger
rki
berlin
germani
use
posit
control
previous
describ
isol
total
nucleic
acid
purifi
nucleic
acid
elut
total
elut
buffer
use
templat
rtpcrelisa
procedur
previous
describ
determin
analyt
sensit
cultur
supernat
dilut
tenfold
logarithm
step
nacl
dilut
factor
nucleic
acid
prepar
dilut
seri
describ
test
accord
protocol
mrtpcrelisa
singl
primer
rtpcrelisa
see
individu
rtpcr
procedur
primer
pair
specif
one
organ
classifi
describ
see
analysi
pcr
product
classif
result
target
sequenc
region
amplif
predominantli
select
literatur
necessari
adapt
multiplex
pcr
protocol
tabl
rt
perform
use
superscript
ii
revers
transcriptas
invitrogen
min
follow
min
min
final
chill
rt
pcr
perform
biorad
icycl
biorad
laboratori
gmbh
munich
germani
perkinelm
geneamp
pcr
system
thermocycl
perkinelm
branchburg
nj
usa
pcr
accuprim
tm
taq
dna
polymeras
system
invitrogen
gmbh
karlsruh
germani
use
pcr
perform
parallel
two
tube
contain
primer
mix
mix
b
respect
primer
concentr
use
mix
given
tabl
sequenc
shown
tabl
setup
pcr
mixtur
reaction
perform
ice
follow
mix
nucleasefre
water
promega
gmbh
mannheim
germani
pcr
buffer
accuprim
system
invitrogen
primer
mix
accuprim
taq
dna
polymeras
invitrogen
roch
diagnost
germani
mix
b
volum
nucleasefre
water
pcr
buffer
primer
mix
b
accuprim
taq
dna
polymeras
invitrogen
mix
b
transfer
new
pcr
tube
cdna
rt
reaction
ad
pcr
templat
mix
ad
remain
cdna
rt
tube
protocol
pcr
min
activ
afterward
cycl
follow
one
final
extens
min
cool
step
ramp
time
adjust
follow
heat
cool
heat
perform
mrtpcr
optim
use
accuprim
system
invitrogen
enzym
differ
thermocycl
may
need
adapt
especi
ramp
time
thermocycl
may
differ
control
neg
control
blank
reagent
contain
h
use
instead
nucleic
acid
posit
control
mrtpcr
run
total
cellular
nucleic
acid
extract
viru
andor
bacteri
stock
use
templat
pandem
influenza
viru
later
includ
mrtpcrelisa
although
rapid
test
use
tool
pandem
influenza
diagnosi
expert
still
recommend
rtpcr
test
primer
use
recommend
german
nation
refer
center
influenza
integr
mix
b
mrtpcrelisa
instead
reoviru
primer
probe
perform
pcr
singl
primer
pcr
multiplex
approach
test
first
posit
control
materi
deriv
german
nation
refer
center
influenza
later
mrtpcrelisa
compar
realtim
format
rtpcr
posit
clinic
specimen
singl
primer
rtpcrelisa
specif
one
organ
perform
previous
describ
individu
pcr
procedur
comparison
mrtpcrelisa
perform
institut
virolog
erasmu
mc
rotterdam
dr
niester
comparison
pcr
b
pertussi
b
parapertussi
perform
kiel
describ
previous
electrophoret
separ
pcr
product
microwel
hybrid
analysi
perform
previous
describ
sequenc
concentr
use
captur
probe
given
tabl
detect
rsv
four
detect
probe
use
combin
one
hybrid
buffer
second
hybrid
buffer
likewis
two
captur
probe
reoviru
coronaviru
combin
one
hybrid
mix
optic
densiti
measur
od
refer
od
run
consid
valid
neg
control
valu
od
unit
od
classif
result
perform
previous
describ
complet
mrtpcrelisa
procedur
guid
excelbas
softwar
calcul
volum
rtpcr
give
pipet
pattern
elisa
microwel
plate
well
classif
elisa
result
describ
prevent
carryov
contamin
within
laboratori
precaut
taken
previous
describ
viru
isol
perform
tertiari
monkey
kidney
tmk
human
embryo
lung
cell
cell
mdck
cell
h
cultur
one
glass
slide
specimen
test
indirect
immunofluoresc
assay
idfa
cultur
follow
maximum
day
summar
broad
spectrum
organ
detect
mrtpcrelisa
make
difficult
defin
one
method
gold
standard
aricaus
pathogen
rhinovirus
exampl
difficult
cultur
differenti
enterovirus
even
actcccaaagttgatgaaagat
aaagaattaggtgcaaccagtc
picorna
gcattcaggggccggag
pan
acaagttcatggcccaatcatgactcg
problemat
even
rtpcr
case
untransl
region
use
target
sequenc
differenti
accomplish
hybrid
therefor
standard
organ
first
establish
diagnosi
organ
picornaviru
group
case
differ
classif
nucleic
acid
sequenc
question
organ
determin
inform
use
defin
gold
standard
sequenc
inform
specimen
contain
mpv
also
determin
factor
gold
standard
differ
two
method
detect
sequenc
pcr
fragment
perform
sequenc
servic
qiagen
hilden
germani
cultur
result
cytopath
effect
andor
idfa
histor
andor
retest
use
gold
standard
cpn
mpn
iva
ivb
rsv
mpv
av
bp
bpp
cultur
result
andor
bordetellaspecif
individu
pcr
defin
gold
standard
lpn
case
specifi
posit
result
one
diagnost
test
urinari
antigen
test
cultur
pcr
defin
gold
standard
due
fact
difficult
even
imposs
detect
one
pathogen
within
one
specimen
cultur
method
rtpcr
techniqu
use
singl
primer
multipl
detect
pathogen
one
specimen
mrtpcrelisa
classifi
follow
singl
organ
detect
cultur
detect
mrtpcr
elisa
result
concord
also
addit
organ
detect
multiplex
approach
addit
organ
proven
individu
singl
primer
pcr
andor
sequenc
pcr
fragment
secondari
tertiari
organ
specimen
defin
correct
well
result
mrtpcrelisa
blind
specimen
sent
cooper
laboratori
specimen
receiv
subsequ
content
sampl
disclos
total
number
sampl
number
sampl
refer
pathogen
use
calcul
sensit
specif
posit
neg
predict
valu
retest
parallel
cultur
mrtpcrelisa
accord
central
limit
theorem
biostatist
mean
mean
percentag
becom
normal
distribut
sampl
size
therefor
aim
test
least
sampl
pathogen
obtain
robust
estim
refer
paramet
figur
show
agaros
gel
rtpcr
posit
control
upper
part
divid
mix
b
clinic
specimen
lower
part
divid
mix
b
fragment
size
pathogen
mix
alloc
list
tabl
correl
fragment
size
elisa
signal
base
hybrid
pathogenspecif
probe
clearli
visibl
pathogen
also
test
individu
rtpcrelisa
crossreact
could
detect
pathogen
test
result
determin
posit
gel
elisa
posit
identif
organ
cell
cultur
supernat
cell
cultur
supernat
previous
describ
use
valid
previous
describ
mrtpcr
test
mrtpcrelisa
specimen
av
ev
iva
ivb
test
respect
pathogen
correctli
describ
addit
one
iva
detect
method
detect
mrtpcrelisa
method
one
specimen
posit
ivb
also
analyt
sensit
mrtpcrelisa
tabl
correspond
singl
primer
rtpcrelisa
test
nucleic
acid
prepar
serial
tenfold
dilut
cultur
supernat
multiplex
amount
templat
present
rtpcr
reaction
correspond
amount
templat
present
cultur
supernat
valu
determin
ml
cultur
dilut
experi
reveal
mrtpcrelisa
comparison
cultur
less
sensit
sensit
cpn
ev
mpv
rsv
sensit
av
iva
ivb
comparison
singl
primer
test
multiplex
approach
show
higher
sensit
detect
cpn
singl
primer
test
sensit
pathogen
use
pcr
protocol
sensit
could
increas
see
tabl
tabl
sensit
clinic
specimen
rotterdam
cv
mpv
picornavirus
evrv
iva
specif
mrtpcrelisa
organ
five
rv
posit
mrtpcrelisa
test
sequenc
two
first
set
specimen
rotterdam
test
rv
cultur
thu
possibl
specimen
detect
correctli
cultur
ivb
cv
mpv
detect
correctli
respect
sensit
b
pertussi
b
parapertussi
test
comparison
cultur
andor
individu
singl
pcr
respect
mean
sensit
method
calcul
result
group
pathogen
without
cpn
mpn
lpn
median
rang
specimen
avail
reovirus
test
perform
lpn
sensit
one
bear
mind
gold
standard
detect
lpn
base
result
histor
perform
test
cultur
pcr
urinari
antigen
test
noteworthi
parallel
retest
specimen
haarlem
gener
fail
specimen
neg
retest
specimen
could
identifi
posit
cultur
two
specimen
identifi
posit
lpnspecif
individu
singl
pcr
contrast
mrtpcrelisa
correctli
detect
lpn
eight
specimen
cpn
mpn
clinic
specimen
avail
thu
result
present
tabl
taken
blind
test
cultur
supernat
take
account
result
avail
includ
cpn
mpn
lpn
overal
sensit
specif
mean
respect
order
evalu
feasibl
mrtpcrelisa
surveil
clinic
specimen
test
prospect
predominantli
nasopharyng
aspir
nasopharyng
swab
bal
nacl
hospit
children
detect
limit
clinic
specimen
approxim
cycl
threshold
ct
valu
specimen
identifi
realtim
assay
ct
valu
could
detect
multiplex
approach
perform
cycl
mrtpcr
reveal
evid
simultan
infect
one
organ
ari
pathogen
detect
specimen
specimen
posit
singl
pathogen
one
pathogen
detect
specimen
test
posit
two
pathogen
three
four
specimen
five
six
seven
pathogen
av
ev
cv
bp
bpp
among
common
microorgan
observ
specimen
test
posit
multipl
pathogen
order
provid
techniqu
rapid
detect
wide
array
noncolon
organ
former
mrtpcrelisa
method
extend
includ
ten
addit
pathogen
test
possibl
detect
noncolon
organ
upper
respiratori
tract
one
mrtpcr
protocol
assess
integr
primer
pair
probe
extend
mrtpcr
assay
rna
dna
viral
bacteri
stock
assay
presenc
nonhomolog
primer
pair
crossreact
detect
document
high
degre
specif
assay
posit
control
pathogen
could
clearli
detect
method
unfortun
singl
local
laboratori
routin
use
convent
techniqu
pathogen
valid
method
directli
incom
specimen
therefor
multistep
approach
involv
sever
institut
bacteriologist
virologist
use
crude
test
cell
cultur
supernat
test
analyt
sensit
ii
perform
verifi
test
gener
evalu
sensit
chosen
primer
use
singl
multiplex
format
retrospect
studi
clinic
specimen
comparison
cultur
iii
includ
individu
mono
rtpcr
conduct
determin
clinic
sensit
feasibl
method
iv
epidemiolog
approach
test
prospect
clinic
specimen
pathogen
cultur
supernat
detect
describ
extens
spectrum
pathogen
method
also
detect
virus
plu
one
iva
possibl
due
slightli
higher
sensit
spectrum
enterovirus
includ
coxsacki
type
type
echo
viru
type
differ
influenza
virus
type
b
furthermor
test
differ
type
adenovirus
reveal
test
type
could
detect
sequenc
align
primer
probe
use
eg
enteroviru
influenza
virus
other
reveal
capabl
detect
mani
type
human
pathogen
within
group
primer
use
influenza
describ
tabl
abl
detect
avian
viru
separ
primer
pair
probe
use
case
human
infect
import
test
pathogen
directli
singl
primer
pcr
prompt
histori
exposur
addit
mrtpcr
assay
possibl
integr
primer
probe
detect
sar
coronavirus
distinct
amplif
product
bp
posit
elisa
signal
could
detect
inactiv
human
serum
contain
sar
coronaviru
shown
fig
lane
mix
b
sar
primer
describ
drosten
et
al
human
serum
rna
transcript
control
experi
kindli
provid
prof
drosten
institut
virolog
univers
bonn
medic
centr
bonn
germani
howev
lab
kiel
mainz
equip
handl
materi
potenti
contain
sar
thu
diagnost
sar
mrtpcrelisa
offer
routin
diagnost
analyt
sensit
test
serial
tenfold
dilut
cultur
supernat
result
valu
determin
cultur
avail
nine
pathogen
mrtpcr
case
compar
sensit
compar
cultur
mrtpcrelisa
show
lower
sensit
versu
cultur
sinc
singl
primer
rtpcr
elisa
show
tenfold
higher
sensit
compar
multiplex
approach
one
must
assum
reduc
sensit
base
use
multiplex
approach
rather
design
primer
discuss
earlier
fgene
primer
origin
use
mrtpcr
chang
hemagglutininneuraminidas
gene
primer
describ
et
al
fgene
primer
fail
detect
clinic
specimen
extend
mrtpcr
use
hemagglutininneuraminidas
gene
target
sequenc
latter
gave
compar
result
analyt
sensit
cultur
also
cpn
singl
primer
detect
sensit
factor
ten
iva
ivb
av
mrtpcrelisa
sensit
compar
cultur
approach
comparison
cultur
supernat
sampl
frozen
year
determin
analyt
sensit
mrtpcrelisa
therefor
analyt
sensit
might
even
underestim
summari
base
result
multiplex
approach
less
sensit
factor
pathogen
comparison
singl
primer
rtpcr
appear
quit
accept
use
method
clinic
routin
sensit
could
enhanc
increas
cycl
number
howev
may
result
weak
unspecif
fragment
agaros
gel
multiplex
approach
especi
viscou
andor
mucou
specimen
therefor
multiplex
method
perform
cycl
confirm
specimen
question
result
elisa
weak
fragment
agaros
gel
singl
primer
rtpcr
cycl
sensit
cycl
comparison
test
pathogen
commonli
identifi
rv
consist
studi
children
acut
respiratori
tract
infect
rais
question
extent
presenc
rv
repres
carriag
incub
convalesc
unknown
even
detect
viru
lower
respiratori
tract
proof
diseasecaus
abil
nevertheless
high
frequenc
rv
identifi
nasopharyng
specimen
infant
young
children
admit
hospit
ari
suggest
caus
correl
agent
observ
ari
symptom
definit
support
consid
rv
true
ari
pathogen
come
fact
situ
hybrid
demonstr
rv
may
trigger
inflammatori
process
infect
cell
tissu
futur
studi
show
specif
microorgan
date
consid
true
pathogen
may
fact
colon
certain
popul
specif
circumst
evid
simultan
detect
nucleic
acid
two
pathogen
within
one
specimen
children
ari
observ
mrtpcr
specimen
simultan
detect
frequent
cv
av
ev
bp
simultan
detect
also
observ
other
use
molecular
techniqu
multiplex
format
howev
result
simultan
detect
judg
care
mrtpcr
like
nonquantit
pcrbase
techniqu
detect
fragment
nucleic
acid
thu
posit
pcr
result
allow
conclus
specif
part
genom
pathogen
present
possibl
draw
conclus
viabil
respect
pathogen
quantit
pcr
assay
advantag
calcul
amount
pathogen
present
specimen
roughli
respiratori
specimen
may
give
addit
guidanc
judg
whether
pathogen
fact
respons
infect
specimen
eg
lower
respiratori
tract
may
contain
encapsul
materi
possibl
nonviabl
pathogen
earlier
infect
present
also
pathogen
adenovirus
may
persist
airway
long
time
without
caus
diseas
epidemiolog
pattern
ari
pathogen
detect
mrtpcr
taken
fig
show
timelimit
yearli
epidem
rsv
mpv
iva
well
yearround
endem
presenc
rv
ev
av
detail
analysi
season
epidemiolog
pathogen
detect
method
publish
elsewher
mrtpcrelisa
evalu
improv
diagnost
yield
term
overal
sensit
well
spectrum
coverag
diagnos
respiratori
infect
perform
littl
requir
equip
low
cost
approxim
includ
materi
like
tip
glove
also
retest
specimen
given
lack
specif
clinic
symptom
associ
ari
caus
organ
multiplex
molecular
test
becom
commonplac
develop
mrtpcrelisa
focu
inclus
newer
respiratori
pathogen
like
coronaviru
bocavirus
although
clinic
relev
latter
still
evalu
also
integr
primer
detect
new
virus
like
pandem
influenza
strain
possibl
enabl
differenti
pandem
infecti
agent
other
